Janssen Biotech, Inc.

Hanssen Biotech, Inc

Michael Diem

Steven Jacobs

Karyn O'Neil

Linus Hyun

Donna Klein

Ricardo Attar

Sheri Moores

Manuel Sepulveda

Rebecca Hawkins

Kristen Picha

Alastair King

Mark L Anderson

Shalom Goldberg

Rosa Cardoso

Tracy Spinka-Doms

Jinquan Luo

Alexey Teplyakov

Francois Gaudet

Thomas Rutkoski

Ronan McDaid

Sheng-Jiun Wu

Chichi Huang

Yingzhe Li

Anthony A Armstrong

Glenn Mark Anderson

Jill Marie Mooney

Benjamin J Harman

Michael Dennis Feldkamp

Jennifer Nemeth-Seay

Steven Pomerantz

Lauren Boucher

Galla Chandra Rao

Leopoldo Luistro

Anderson Mark

Priyanka Nair-Gupta

Karyn O'neil

Ronan Mcdaid

Mark Anderson

Karen O'NEIL

Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

EGFR and C-met fibronectin type III domain binding molecules

FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

CD137 binding fibronectin type III domains

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Prostate specific membrane antigen binding fibronectin type iii domains

Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Serum albumin-binding fibronectin type III domains

Disclosed are materials and methods for improved single chain variable fragments.

Materials and methods for improved single chain variable fragments

Anti-CD33 antibodies and antigen-binding fragments thereof and anti-CD33/anti-CD3 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof

FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

PD-L1 binding fibronectin type III domains

EGFR and c-Met fibronectin type III domain binding molecules

Provided herein are isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.

Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

Prostate specific membrane antigen binding fibronectin type III domains

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Cysteine engineered fibronectin type III domain binding molecules

Growing community of inventors

Havertown, PA, United States of America

Michael Diem